Vistagen Therapeutics Inc (VTGN)

$0.61 -0.02 (-3.73%)
Market Cap 24.06M
Revenue (ttm) 490,000.00
Net Income (ttm) -51.42M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -10,493.88%
Debt to Equity Ratio 0.00
Volume 471,300
Avg Vol 1,089,876
Day's Range N/A - N/A
Shares Out 39.62M
Stochastic %K 52%
Beta 0.29
Analysts Hold
Price Target $0.97

Company Profile

Vistagen Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development and commercialization of therapies for neuropsychiatric and neurological disorders. The company's product pipeline includes Fasedienol, an investigational pherine nasal spray that is in Phase III clinical trial for the treatment of anxiety in adults with social anxiety disorder; and Itruvone, an odorless synthetic investigational neuroactive pherine nasal spray, which is in Phase II clinical trial...

Industry: Biotechnology
Sector: Healthcare
Phone: 650 577 3600
Address:
343 Allerton Avenue, South San Francisco, United States
AStrokeOfLuck
AStrokeOfLuck Mar. 16 at 2:28 AM
$VTGN
0 · Reply
MaskMaker
MaskMaker Mar. 14 at 9:13 AM
$NXL $VTGN $SAVA $MVIS $4
0 · Reply
MaskMaker
MaskMaker Mar. 14 at 9:11 AM
$NXL $VTGN $GRRR $SAVA
0 · Reply
mb0157
mb0157 Mar. 13 at 11:05 PM
$VTGN. More clues. Why else spend $$$$ as a diamond sponsor. They have no money
2 · Reply
MaskMaker
MaskMaker Mar. 13 at 8:58 PM
$GRRR $NXL $VTGN Silence before the storm
0 · Reply
MaskMaker
MaskMaker Mar. 13 at 8:56 PM
$NXL $GRRR $VTGN $AISP Be Sure to not let Greed rule when it comes to taking profits
0 · Reply
tblags
tblags Mar. 13 at 8:37 PM
$VTGN how soon till they get delisted? I need to set a reminder on my calendar to check this board on that day so I can laugh at everyone shocked that they got effed by a fat reverse split.
0 · Reply
EZ2026
EZ2026 Mar. 13 at 2:37 PM
$VTGN Anyone in on $1.00 Call 8/21? Given the massive recent dip I'd find it hard to believe it couldn't hit around $1 as a rebound before August. Will keep watching for updates tho.
0 · Reply
BioBum
BioBum Mar. 13 at 12:27 AM
$VTGN buyout of $4 a share would be ok with me
2 · Reply
marketCaptain
marketCaptain Mar. 12 at 9:32 AM
$VTGN Just wanted to remind you how hard this is being sold at the yearly vwap. Daily chart
1 · Reply
Latest News on VTGN
Bragar Eagel & Squire, P.C. Urges Vistagen Therapeutics, Inc. Stockholders to Contact the Firm Regarding the Upcoming March 16th Lead Plaintiff Deadline

Mar 11, 2026, 4:36 PM EDT - 4 days ago

Bragar Eagel & Squire, P.C. Urges Vistagen Therapeutics, Inc. Stockholders to Contact the Firm Regarding the Upcoming March 16th Lead Plaintiff Deadline

Vistagen to Participate in Upcoming Investor Conferences

Mar 3, 2026, 8:30 AM EST - 12 days ago

Vistagen to Participate in Upcoming Investor Conferences

Vistagen to Participate in the 46th Annual TD Cowen Healthcare Conference

Feb 25, 2026, 8:30 AM EST - 18 days ago

Vistagen to Participate in the 46th Annual TD Cowen Healthcare Conference

Vistagen Therapeutics, Inc. (VTGN) Q3 2026 Earnings Call Transcript

Feb 12, 2026, 7:44 PM EST - 4 weeks ago

Vistagen Therapeutics, Inc. (VTGN) Q3 2026 Earnings Call Transcript

Vistagen Reports Fiscal Year 2026 Third Quarter Financial Results and Provides Corporate Update

Feb 12, 2026, 4:30 PM EST - 4 weeks ago

Vistagen Reports Fiscal Year 2026 Third Quarter Financial Results and Provides Corporate Update

UPCOMING DEADLINE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Vistagen Therapeutics

Feb 9, 2026, 5:21 PM EST - 4 weeks ago

UPCOMING DEADLINE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Vistagen Therapeutics

VTGN Investors Encouraged to Seek Lead Plaintiff Role in Vistagen Therapeutics Securities Class Actoin Case with Johnson Fistel

Feb 6, 2026, 9:52 AM EST - 5 weeks ago

VTGN Investors Encouraged to Seek Lead Plaintiff Role in Vistagen Therapeutics Securities Class Actoin Case with Johnson Fistel

Vistagen to Report Fiscal Year 2026 Third Quarter Results and Host Corporate Update Conference Call on February 12, 2026

Feb 4, 2026, 8:30 AM EST - 5 weeks ago

Vistagen to Report Fiscal Year 2026 Third Quarter Results and Host Corporate Update Conference Call on February 12, 2026

INVESTOR NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Vistagen Therapeutics

Jan 29, 2026, 8:24 AM EST - 6 weeks ago

INVESTOR NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Vistagen Therapeutics

VISTAGEN THERAPEUTICS, INC. (NASDAQ: VTGN) DEADLINE ALERT – Bernstein Liebhard LLP Reminds Vistagen Therapeutics, Inc. Investors of Upcoming Deadline

Jan 22, 2026, 10:45 AM EST - 7 weeks ago

VISTAGEN THERAPEUTICS, INC. (NASDAQ: VTGN) DEADLINE ALERT – Bernstein Liebhard LLP Reminds Vistagen Therapeutics, Inc. Investors of Upcoming Deadline

VISTAGEN THERAPEUTICS, INC. (NASDAQ: VTGN) INVESTOR ALERT Investors With Large Losses in Vistagen Therapeutics, Inc. Should Contact Bernstein Liebhard LLP To Discuss Their Rights

Jan 16, 2026, 5:06 PM EST - 2 months ago

VISTAGEN THERAPEUTICS, INC. (NASDAQ: VTGN) INVESTOR ALERT Investors With Large Losses in Vistagen Therapeutics, Inc. Should Contact Bernstein Liebhard LLP To Discuss Their Rights

Vistagen's Social Anxiety Disorder Drug Disappoints In Pivotal Late-Stage Study

Dec 17, 2025, 12:42 PM EST - 3 months ago

Vistagen's Social Anxiety Disorder Drug Disappoints In Pivotal Late-Stage Study

Vistagen Announces Topline Results from PALISADE-3 Phase 3 Public Speaking Challenge Study of Fasedienol for the Acute Treatment of Social Anxiety Disorder

Dec 17, 2025, 8:30 AM EST - 3 months ago

Vistagen Announces Topline Results from PALISADE-3 Phase 3 Public Speaking Challenge Study of Fasedienol for the Acute Treatment of Social Anxiety Disorder

Vistagen Appoints Nick Tressler as Chief Financial Officer

Dec 1, 2025, 8:30 AM EST - 3 months ago

Vistagen Appoints Nick Tressler as Chief Financial Officer

Vistagen Reports Findings on PH80's Brain and Autonomic Effects in Women with Menopausal Hot Flashes at The Menopause Society 2025 Annual Meeting

Nov 26, 2025, 8:30 AM EST - 3 months ago

Vistagen Reports Findings on PH80's Brain and Autonomic Effects in Women with Menopausal Hot Flashes at The Menopause Society 2025 Annual Meeting

Vistagen Therapeutics: Intranasal Pherines And A Make-Or-Break 2026

Nov 18, 2025, 7:45 AM EST - 4 months ago

Vistagen Therapeutics: Intranasal Pherines And A Make-Or-Break 2026

Vistagen Therapeutics, Inc. (VTGN) Q2 2026 Earnings Call Transcript

Nov 13, 2025, 7:01 PM EST - 4 months ago

Vistagen Therapeutics, Inc. (VTGN) Q2 2026 Earnings Call Transcript

Vistagen Reports Fiscal Year 2026 Second Quarter Financial Results and Provides Corporate Update

Nov 13, 2025, 4:30 PM EST - 4 months ago

Vistagen Reports Fiscal Year 2026 Second Quarter Financial Results and Provides Corporate Update

Vistagen to Report Fiscal Year 2026 Second Quarter Results and Host Corporate Update Conference Call on November 13, 2025

Nov 10, 2025, 8:30 AM EST - 4 months ago

Vistagen to Report Fiscal Year 2026 Second Quarter Results and Host Corporate Update Conference Call on November 13, 2025

Vistagen to Participate in Stifel Healthcare Conference 2025

Nov 5, 2025, 8:30 AM EST - 4 months ago

Vistagen to Participate in Stifel Healthcare Conference 2025

Vistagen Completes PALISADE-3 Phase 3 Public Speaking Challenge Study for the Acute Treatment of Social Anxiety Disorder

Nov 3, 2025, 8:30 AM EST - 4 months ago

Vistagen Completes PALISADE-3 Phase 3 Public Speaking Challenge Study for the Acute Treatment of Social Anxiety Disorder

Vistagen Appoints Paul Edick to its Board of Directors

Oct 29, 2025, 8:30 AM EDT - 4 months ago

Vistagen Appoints Paul Edick to its Board of Directors

Vistagen to Present at The Menopause Society 2025 Annual Meeting

Oct 16, 2025, 8:30 AM EDT - 5 months ago

Vistagen to Present at The Menopause Society 2025 Annual Meeting

Vistagen to Present at the TD Cowen 5th Annual Novel Mechanisms in Neuropsychiatry & Epilepsy Summit

Sep 9, 2025, 8:30 AM EDT - 6 months ago

Vistagen to Present at the TD Cowen 5th Annual Novel Mechanisms in Neuropsychiatry & Epilepsy Summit

Vistagen Therapeutics, Inc. (VTGN) Q1 2026 Earnings Call Transcript

Aug 8, 2025, 2:13 PM EDT - 7 months ago

Vistagen Therapeutics, Inc. (VTGN) Q1 2026 Earnings Call Transcript

Vistagen Reports Fiscal Year 2026 First Quarter Financial Results and Corporate Update

Aug 7, 2025, 4:30 PM EDT - 7 months ago

Vistagen Reports Fiscal Year 2026 First Quarter Financial Results and Corporate Update

Vistagen to Report Fiscal Year 2026 First Quarter Results and Host Corporate Update Conference Call on August 7, 2025

Jul 31, 2025, 8:30 AM EDT - 8 months ago

Vistagen to Report Fiscal Year 2026 First Quarter Results and Host Corporate Update Conference Call on August 7, 2025

Vistagen to Present at the BTIG Virtual Biotechnology Conference

Jul 24, 2025, 8:30 AM EDT - 8 months ago

Vistagen to Present at the BTIG Virtual Biotechnology Conference

Vistagen Honored for Outstanding Workplace Culture and Mental Health Leadership

Jul 15, 2025, 8:30 AM EDT - 8 months ago

Vistagen Honored for Outstanding Workplace Culture and Mental Health Leadership

Vistagen Appoints Elissa Cote as Chief Corporate Development Officer

Jun 25, 2025, 8:30 AM EDT - 9 months ago

Vistagen Appoints Elissa Cote as Chief Corporate Development Officer

Vistagen Therapeutics, Inc. (VTGN) Q4 2025 Earnings Call Transcript

Jun 17, 2025, 6:49 PM EDT - 9 months ago

Vistagen Therapeutics, Inc. (VTGN) Q4 2025 Earnings Call Transcript

Vistagen Reports Fiscal Year 2025 Financial Results and Provides Corporate Update

Jun 17, 2025, 4:30 PM EDT - 9 months ago

Vistagen Reports Fiscal Year 2025 Financial Results and Provides Corporate Update

Vistagen to Report Fiscal Year 2025 Financial Results and Host Corporate Update Conference Call on June 17, 2025

Jun 12, 2025, 8:30 AM EDT - 9 months ago

Vistagen to Report Fiscal Year 2025 Financial Results and Host Corporate Update Conference Call on June 17, 2025

Vistagen on Track to Deliver Topline Data From Fasedienol PALISADE-3 Phase 3 Trial for Acute Treatment of Social Anxiety Disorder in the Fourth Quarter of This Year

Jun 2, 2025, 8:30 AM EDT - 10 months ago

Vistagen on Track to Deliver Topline Data From Fasedienol PALISADE-3 Phase 3 Trial for Acute Treatment of Social Anxiety Disorder in the Fourth Quarter of This Year

Vistagen to Present at the Jefferies 2025 Global Life Sciences Conference New York

May 28, 2025, 8:30 AM EDT - 10 months ago

Vistagen to Present at the Jefferies 2025 Global Life Sciences Conference New York

Vistagen to Present at the 2025 American Society of Clinical Psychopharmacology Conference

May 23, 2025, 8:30 AM EDT - 10 months ago

Vistagen to Present at the 2025 American Society of Clinical Psychopharmacology Conference

Vistagen Presents New Research on the Impact of Social Anxiety Disorder at The Anxiety and Depression Association 2025 Conference

Apr 17, 2025, 8:30 AM EDT - 11 months ago

Vistagen Presents New Research on the Impact of Social Anxiety Disorder at The Anxiety and Depression Association 2025 Conference

Vistagen to Present at the 2025 Anxiety and Depression Association Conference

Mar 19, 2025, 8:30 AM EDT - 1 year ago

Vistagen to Present at the 2025 Anxiety and Depression Association Conference

Vistagen to Participate in Stifel 2025 Virtual CNS Forum

Mar 4, 2025, 8:30 AM EST - 1 year ago

Vistagen to Participate in Stifel 2025 Virtual CNS Forum

Vistagen to Participate in the 45th Annual TD Cowen Healthcare Conference

Feb 20, 2025, 8:30 AM EST - 1 year ago

Vistagen to Participate in the 45th Annual TD Cowen Healthcare Conference

Vistagen: Pherine Candidate Proof Of Concept Continues With Fifth Indication

Feb 14, 2025, 6:19 PM EST - 1 year ago

Vistagen: Pherine Candidate Proof Of Concept Continues With Fifth Indication

AStrokeOfLuck
AStrokeOfLuck Mar. 16 at 2:28 AM
$VTGN
0 · Reply
MaskMaker
MaskMaker Mar. 14 at 9:13 AM
$NXL $VTGN $SAVA $MVIS $4
0 · Reply
MaskMaker
MaskMaker Mar. 14 at 9:11 AM
$NXL $VTGN $GRRR $SAVA
0 · Reply
mb0157
mb0157 Mar. 13 at 11:05 PM
$VTGN. More clues. Why else spend $$$$ as a diamond sponsor. They have no money
2 · Reply
MaskMaker
MaskMaker Mar. 13 at 8:58 PM
$GRRR $NXL $VTGN Silence before the storm
0 · Reply
MaskMaker
MaskMaker Mar. 13 at 8:56 PM
$NXL $GRRR $VTGN $AISP Be Sure to not let Greed rule when it comes to taking profits
0 · Reply
tblags
tblags Mar. 13 at 8:37 PM
$VTGN how soon till they get delisted? I need to set a reminder on my calendar to check this board on that day so I can laugh at everyone shocked that they got effed by a fat reverse split.
0 · Reply
EZ2026
EZ2026 Mar. 13 at 2:37 PM
$VTGN Anyone in on $1.00 Call 8/21? Given the massive recent dip I'd find it hard to believe it couldn't hit around $1 as a rebound before August. Will keep watching for updates tho.
0 · Reply
BioBum
BioBum Mar. 13 at 12:27 AM
$VTGN buyout of $4 a share would be ok with me
2 · Reply
marketCaptain
marketCaptain Mar. 12 at 9:32 AM
$VTGN Just wanted to remind you how hard this is being sold at the yearly vwap. Daily chart
1 · Reply
ThaDankles
ThaDankles Mar. 12 at 5:22 AM
$VTGN aquisition incoming
1 · Reply
ThaDankles
ThaDankles Mar. 12 at 5:19 AM
$VTGN i believe
0 · Reply
MaskMaker
MaskMaker Mar. 11 at 10:29 PM
$NXL Accumulation Period I think it’s being slowly Accumulated Insiders Bought millions at Double the price $GRRR $VTGN
0 · Reply
mb0157
mb0157 Mar. 11 at 8:45 PM
$VTGN. More clues. Next week is big!! Also March 16 is lawsuit day. They want to shut this down.
1 · Reply
marketCaptain
marketCaptain Mar. 11 at 7:56 PM
$VTGN NDA approval and this makes a new 5 year high
0 · Reply
marketCaptain
marketCaptain Mar. 11 at 7:55 PM
$VTGN The accumulation is wild
0 · Reply
maxximil
maxximil Mar. 11 at 5:57 PM
$VTGN 18k+ followers and it is still sitting this low?
0 · Reply
maxximil
maxximil Mar. 11 at 5:57 PM
$VTGN ok now time to fly?
0 · Reply
RicoTrading
RicoTrading Mar. 11 at 12:10 PM
$VTGN VistaGen implemented a board-approved workforce reduction of about 20%. The change is intended to manage cash while prioritizing ongoing clinical studies in its PALISADE program for fasedienol for acute treatment of social anxiety disorder. The company said it expects topline results from the PALISADE-4 Phase 3 trial in the first half of 2026 and expects cash runway into 2027. Affected employees may receive cash severance and temporary healthcare coverage if they sign a separation agreement that includes a general release of claims.
0 · Reply
BioBum
BioBum Mar. 10 at 12:22 AM
$VTGN May set a record for most failed phase 3 trials
1 · Reply
holmyown01
holmyown01 Mar. 9 at 3:48 PM
$VTGN is P4 results still on track for Juneish?
0 · Reply
MaskMaker
MaskMaker Mar. 9 at 9:18 AM
$NXL Revolutionizing Mental Health Treatments $VTGN
0 · Reply